AUVI-Q (epinephrine) by Fresenius Kabi is adrenergic alpha-agonists [moa]. First approved in 2012.
Drug data last refreshed 8h ago · AI intelligence enriched 10h ago
AUVI-Q is an auto-injectable epinephrine solution approved for emergency treatment of anaphylaxis and severe allergic reactions. It works as an alpha-adrenergic agonist, rapidly counteracting anaphylactic symptoms by stimulating adrenergic receptors. The product represents a convenient, pre-filled auto-injector delivery format for a well-established emergency therapeutic.
Product is in peak lifecycle stage with modest Part D utilization; brand team size likely stable with focus on maintaining market position rather than aggressive expansion.
Adrenergic alpha-Agonists
alpha-Adrenergic Agonist
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Continuous Versus Bolus Norepinephrine Administration to Treat Postinduction Hypotension
Study Comparing Glycerin With 1% Lidocaine and Epinephrine Versus Glycerin With 1% Lidocaine Without Epinephrine for the Sclerotherapy of Leg Telangiectasias
Hemodynamic Effects of Norepinephrine Reduction on Critical Closing Pressure in Distributive Shock
Pneumatic Leg Compression and Norepinephrine Requirements in Patients Having Non-cardiac Surgery
Treating Intraoperative Bradycardia in Non-cardiac Surgery Patients With Atropine at Heart Rates Below 60 Versus 30 Beats Per Minute and Norepinephrine Requirements
Worked on AUVI-Q at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moAUVI-Q roles offer stable, mature-stage product experience with focus on market maintenance, patient access, and anaphylaxis awareness programs. Career growth will be driven by market defense, pricing strategy, and payer relationships rather than blockbuster-level commercial scale.